Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Prostate Adenocarcinoma × Radium-223 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 9 Prostate Adenocarcinoma 1 Pain 1 Castration-resistant Prostate Cancer 1 Biochemical Recurrent Prostate Cancer 1

Interventions

luprolide acetate gel depot 3 Magnetic Resonance Spectroscopy 3 Specimen Handling 2 Leuprolide 2 Goserelin 2 Biopsy 2 relugolix 1 radium Ra 223 dichloride 1 niraparib 1 gallium 68 PSMA-11 1 fluciclovine F-18 1 flibanserin 1 enzalutamide 1 atezolizumab 1 apalutamide 1 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 abiraterone 1 X-Rays 1 Triptorelin Pamoate 1 Radium-223 1 Radiotherapy, Image-Guided 1 Radiotherapy 1 Radiosurgery 1 Radiation 1 Prednisone 1 PROSTVAC 1 Methods 1 Lymph Node Excision 1 Glutamate Carboxypeptidase II 1 Estramustine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04704505 2026-02-06

BAT-RAD

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡